PASG stock icon

Passage Bio
PASG

0.5795 USD
-0.0165
2.77%
At close Oct 18, 4:00 PM EDT
After hours
0.5904
+0.0109
1.88%
1 day
-2.77%
5 days
-6.06%
1 month
-17.33%
3 months
-34.89%
6 months
-51.71%
Year to date
-35.69%
1 year
-12.06%
5 years
-97.39%
 

About: Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.

Employees: 85

Healthcare Biological Products, Except Diagnostic Substances
0
Funds holding %
of 6,740 funds
–
Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

6.74% less ownership

Funds ownership: 68.1% [Q1] → 61.36% (-6.74%) [Q2]

12% less funds holding

Funds holding: 50 [Q1] → 44 (-6) [Q2]

27% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 11

41% less capital invested

Capital invested by funds: $51.1M [Q1] → $30M (-$21.1M) [Q2]

67% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 9

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$7
1,108%
upside
Avg. target
$7
1,108%
upside
High target
$7
1,108%
upside

1 analyst rating

1 positive
100%
0 neutral
0%
0 negative
0%
Rodman & Renshaw
1,108%upside
$7
Buy
Initiated
3 Sept 2024
See Analyst Rankings

Financial journalist opinion

Neutral
GlobeNewsWire
3 weeks ago
Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Chardan's 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 8:30 a.m. ET.
Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference
Neutral
GlobeNewsWire
1 month ago
Passage Bio Welcomes Tom Kassberg to Board of Directors
PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Mr. Kassberg is currently Chief Business Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultrarare genetic diseases.
Passage Bio Welcomes Tom Kassberg to Board of Directors
Neutral
GlobeNewsWire
1 month ago
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
PHILADELPHIA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 7:00 a.m. ET.
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
Neutral
GlobeNewsWire
2 months ago
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Enrolled first FTD-GRN patient in Cohort 2 in upliFT-D trial Plan to present updated safety and biomarker data from Cohort 1 FTD-GRN patients treated with PBFT02 at 14th International Conference on Frontotemporal Dementias (ISFTD2024) in September 2024 Achieved alignment with Food and Drug Administration (FDA) on the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Completed out-licensing of pediatric lysosomal storage disease programs to GEMMA Biotherapeutics Strong balance sheet to support continued execution, with cash runway to fund operations extended to the end of Q2 2026 PHILADELPHIA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2024 and provided recent business highlights. “This has been a pivotal quarter for our company, marked by significant momentum in our upliFT-D trial, increased clarity around our strategy to expand PBFT02 into additional adult neurodegenerative indications, and out-licensing of our pediatric lysosomal storage disorder programs,” said Will Chou, M.D.
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Neutral
GlobeNewsWire
2 months ago
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy to GEMMA Biotherapeutics, a new company co-founded by Dr. James M. Wilson
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
Neutral
GlobeNewsWire
3 months ago
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
Negative
Zacks Investment Research
4 months ago
Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Passage Bio (PASG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Neutral
GlobeNewsWire
4 months ago
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 at 4:00 p.m. ET.
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Neutral
GlobeNewsWire
4 months ago
Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award
PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced Carrie Gordon, a sophomore at Drexel University, as the third recipient of its Tachi Yamada Scholarship award.
Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award
Positive
Zacks Investment Research
5 months ago
All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy
Passage Bio (PASG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy
See News Rankings
Charts implemented using Lightweight Charts™